methotrexate - CISMeF

Preferred Label : methotrexate;

MeSH definition : An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA.;

MeSH synonym : amethopterin;

CISMeF synonym : 15475-56-6 (Methotrexate, sodium salt); 7413-34-5 (Methotrexate, disodium salt); disodium salt methotrexate; sodium salt methotrexate;

MeSH hyponym : methotrexate, dicesium salt; Methotrexate, (D)-Isomer; methotrexate hydrate; mexate; Methotrexate, (DL)-Isomer; methotrexate sodium; Sodium, Methotrexate; Methotrexate, Sodium Salt; Methotrexate, Disodium Salt; Hydrate, Methotrexate; Dicesium Salt Methotrexate;

MeSH CAS label : L-Glutamic acid, N-(4-(((2,4-diamino-6-pteridinyl)methyl)methylamino)benzoyl)-;

MeSH Related Number : methotrexate, (D)-Isomer; methotrexate, dicesium salt; methotrexate hydrate; methotrexate, (DL)-Isomer; 133073-73-1 (x.H2O); 15475-56-6 (Na salt); 51865-79-3 ((D)-isomer); 59-05-2 (Methotrexate); 60388-53-6 ((DL)-isomer); 86669-44-5 (di-Cs salt); methotrexate sodium; 3IG1E710ZN;

Registry Number MeSH : 59-05-2;

Related CAS MeSH : 51865-79-3 (Methotrexate, (D)-Isomer); 86669-44-5 (Methotrexate, dicesium salt); 133073-73-1 (Methotrexate hydrate); 60388-53-6 (Methotrexate, (DL)-Isomer); 3IG1E710ZN (Methotrexate sodium);

Wikipedia link : https://en.wikipedia.org/wiki/Methotrexate;

Codes EINECS : 200-413-8;

Is substance : O;

UNII : YL5FZ2Y5U1;

InChIKey : FBOZXECLQNJBKD-ZDUSSCGKSA-N;

Details

Origin ID

D008727;

UMLS CUI

C0025677;

ATC code(s)
- methotrexate [ATC Code]
ATC code(s)
- methotrexate [ATC Code]
- methotrexate [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
CISMeF manual mappings
- Methotrexate adverse reaction (disorder) [SNOMED CT concept]
- Methotrexate poisoning (disorder) [SNOMED CT concept]
- methotrexate [Substance BNPC]
Currated CISMeF NLP mapping
- Methotrexate [LOINC component]
- Methotrexate [ICD-11 Extension code]
- Methotrexate [ICHI extension code]
- Methotrexate [SMS substance]
- Methotrexate [NCIt concept]
- Methotrexate (substance) [SNOMED CT concept]
- methotrexate [SNOMED Notion]
Indexing information
- Slc19a1 protein, rat [MeSH Supplementary Concept]
Manual NTBT mappings (CISMeF)
- Methotrexate and derivative (substance) [Inactive SNOMED CT concept]
Pharmacological action(s)
- abortifacient agents, nonsteroidal [MeSH Descriptor]
- antimetabolites, antineoplastic [MeSH Descriptor]
- antirheumatic agents [MeSH Descriptor]
- dermatologic agents [MeSH Descriptor]
- folic acid antagonists [MeSH Descriptor]
- immunosuppressive agents [MeSH Descriptor]
- nucleic acid synthesis inhibitors [MeSH Descriptor]
- reproductive control agents [MeSH Descriptor]
Record concept(s)
- Methotrexate, (D)-Isomer [MeSH concept]
- Methotrexate, (DL)-Isomer [MeSH concept]
- methotrexate [MeSH concept]
- methotrexate hydrate [MeSH concept]
- methotrexate sodium [MeSH concept]
- methotrexate, dicesium salt [MeSH concept]
- mexate [MeSH concept]
Related MeSH Supplementary Concept(s)
- (COMPADRI)-III protocol [MeSH Supplementary Concept]
- (N-(4-amino-4-deoxy-N(10)-methylpteroyl)amino)-3-chloro-4,5-dihydro-5-isoxazoleacetic acid [MeSH Supplementary Concept]
- 06-Paris-LA-66 protocol [MeSH Supplementary Concept]
- 10-ethylaminopterin [MeSH Supplementary Concept]
- 3',5'-dichloromethotrexate [MeSH Supplementary Concept]
- 3',5'-difluoromethotrexate [MeSH Supplementary Concept]
- 3'-chloromethotrexate [MeSH Supplementary Concept]
- 3M protocol [MeSH Supplementary Concept]
- 4-(N-((2,4-diamino-6-pteridinyl)methyl)amino)benzoic acid [MeSH Supplementary Concept]
- 4-amino-10-methylpteroylhexa-gamma-glutamic acid [MeSH Supplementary Concept]
- 5-deazamethotrexate [MeSH Supplementary Concept]
- 5-hexadecyl methotrexate [MeSH Supplementary Concept]
- 5-monobutyl methotrexate [MeSH Supplementary Concept]
- 7-hydroxydichloromethotrexate [MeSH Supplementary Concept]
- 7-hydroxymethotrexate [MeSH Supplementary Concept]
- A-VBM-FH6 protocol [MeSH Supplementary Concept]
- AAAP protocol [MeSH Supplementary Concept]
- ACFM protocol [MeSH Supplementary Concept]
- ACHM protocol [MeSH Supplementary Concept]
- ACMFVP protocol [MeSH Supplementary Concept]
- ACOMLA protocol [MeSH Supplementary Concept]
- AIEOP 8703 protocol [MeSH Supplementary Concept]
- AIEOP acute lymphoblastic leukemia protocol [MeSH Supplementary Concept]
- AIEOP protocol 8202 [MeSH Supplementary Concept]
- ALHR88 protocol [MeSH Supplementary Concept]
- ALL-80 protocol [MeSH Supplementary Concept]
- ALL-82 protocol [MeSH Supplementary Concept]
- ALL-85 protocol [MeSH Supplementary Concept]
- AMF protocol [MeSH Supplementary Concept]
- ANAVACYM protocol [MeSH Supplementary Concept]
- APO combination [MeSH Supplementary Concept]
- AVTMF protocol [MeSH Supplementary Concept]
- AWO54 [MeSH Supplementary Concept]
- BCMV protocol [MeSH Supplementary Concept]
- BCOMM protocol [MeSH Supplementary Concept]
- BECALM protocol [MeSH Supplementary Concept]
- BEMOP-CA protocol [MeSH Supplementary Concept]
- BFM 78 protocol [MeSH Supplementary Concept]
- BFM-86 protocol [MeSH Supplementary Concept]
- BMC protocol [MeSH Supplementary Concept]
- BMF phase II protocol [MeSH Supplementary Concept]
- BMFt protocol [MeSH Supplementary Concept]
- BMPD protocol [MeSH Supplementary Concept]
- BOMES protocol [MeSH Supplementary Concept]
- BOMM protocol [MeSH Supplementary Concept]
- BOP-CISCA-POMB-ACE regimen [MeSH Supplementary Concept]
- BVAM protocol [MeSH Supplementary Concept]
- BVMM protocol [MeSH Supplementary Concept]
- BVMP regimen [MeSH Supplementary Concept]
- C'MP protocol [MeSH Supplementary Concept]
- CADOM protocol [MeSH Supplementary Concept]
- CAEVM protocol [MeSH Supplementary Concept]
- CAM combination [MeSH Supplementary Concept]
- CAMBO-VIP protocol [MeSH Supplementary Concept]
- CAMELEON protocol [MeSH Supplementary Concept]
- CAMEO protocol [MeSH Supplementary Concept]
- CAMF protocol [MeSH Supplementary Concept]
- CAMFTP protocol [MeSH Supplementary Concept]
- CAMP protocol [MeSH Supplementary Concept]
- CAMP-L protocol [MeSH Supplementary Concept]
- CAPABLE protocol [MeSH Supplementary Concept]
- CARE protocol [MeSH Supplementary Concept]
- CAV-HEM protocol [MeSH Supplementary Concept]
- CBVPM protocol [MeSH Supplementary Concept]
- CCG-141 protocol [MeSH Supplementary Concept]
- CCOM protocol [MeSH Supplementary Concept]
- CEOP-IMVP-Dexa regimen [MeSH Supplementary Concept]
- CEOP-MB protocol [MeSH Supplementary Concept]
- CFMPV protocol [MeSH Supplementary Concept]
- CHAMOMA protocol [MeSH Supplementary Concept]
- CHAMP-5 protocol [MeSH Supplementary Concept]
- CMB protocol [MeSH Supplementary Concept]
- CMED protocol [MeSH Supplementary Concept]
- CMF protocol [MeSH Supplementary Concept]
- CMF regimen [MeSH Supplementary Concept]
- CMF-B protocol [MeSH Supplementary Concept]
- CMFDV protocol [MeSH Supplementary Concept]
- CMFP protocol [MeSH Supplementary Concept]
- CMFPT protocol [MeSH Supplementary Concept]
- CMFPTH regimen [MeSH Supplementary Concept]
- CMFVP protocol [MeSH Supplementary Concept]
- CMU protocol [MeSH Supplementary Concept]
- CMV regimen [MeSH Supplementary Concept]
- CMxMF regimen [MeSH Supplementary Concept]
- CNR-NEO 2 protocol [MeSH Supplementary Concept]
- COMET-A protocol [MeSH Supplementary Concept]
- COMF protocol [MeSH Supplementary Concept]
- COMLA protocol [MeSH Supplementary Concept]
- COMP protocol [MeSH Supplementary Concept]
- COMP-1 protocol [MeSH Supplementary Concept]
- COMP-VAN protocol [MeSH Supplementary Concept]
- COMPA regimen [MeSH Supplementary Concept]
- COMPE protocol [MeSH Supplementary Concept]
- COMVP protocol [MeSH Supplementary Concept]
- COP protocol 1 [MeSH Supplementary Concept]
- COPAD protocol [MeSH Supplementary Concept]
- COPADEM protocol [MeSH Supplementary Concept]
- COSS-86 protocol [MeSH Supplementary Concept]
- CYM protocol [MeSH Supplementary Concept]
- CYOMAD protocol [MeSH Supplementary Concept]
- Carbo-MVE protocol [MeSH Supplementary Concept]
- DAVTHML regimen [MeSH Supplementary Concept]
- DCCM protocol [MeSH Supplementary Concept]
- DD1 protocol [MeSH Supplementary Concept]
- DEMOB protocol [MeSH Supplementary Concept]
- DK226 compound [MeSH Supplementary Concept]
- DTPA-methotrexate [MeSH Supplementary Concept]
- DVP-M-CHOP protocol [MeSH Supplementary Concept]
- EMA-CO protocol [MeSH Supplementary Concept]
- EMACO protocol [MeSH Supplementary Concept]
- EMB protocol [MeSH Supplementary Concept]
- EMLP protocol [MeSH Supplementary Concept]
- EP-OMB protocol [MeSH Supplementary Concept]
- EVM protocol [MeSH Supplementary Concept]
- EpPt-OMB protocol [MeSH Supplementary Concept]
- F-MACHOP protocol [MeSH Supplementary Concept]
- FAC-MV protocol [MeSH Supplementary Concept]
- FEMTX protocol [MeSH Supplementary Concept]
- FEMTX-P protocol [MeSH Supplementary Concept]
- FMVMP regimen [MeSH Supplementary Concept]
- FUM protocol [MeSH Supplementary Concept]
- GAP-POMP regimen [MeSH Supplementary Concept]
- HCVAD protocol [MeSH Supplementary Concept]
- HELP protocol [MeSH Supplementary Concept]
- HM 89 protocol [MeSH Supplementary Concept]
- HM 91 protocol [MeSH Supplementary Concept]
- HMF protocol [MeSH Supplementary Concept]
- HR-1 protocol [MeSH Supplementary Concept]
- HR-2 protocol [MeSH Supplementary Concept]
- HR-3 protocol [MeSH Supplementary Concept]
- HiC-COM protocol [MeSH Supplementary Concept]
- IEVM protocol [MeSH Supplementary Concept]
- IMVP-16 protocol [MeSH Supplementary Concept]
- IVAM regimen [MeSH Supplementary Concept]
- K1 protocol [MeSH Supplementary Concept]
- L-6 protocol [MeSH Supplementary Concept]
- LALA 87 protocol [MeSH Supplementary Concept]
- LBCMVD-56 protocol [MeSH Supplementary Concept]
- LCOMP protocol [MeSH Supplementary Concept]
- LEAMP protocol [MeSH Supplementary Concept]
- LEMP protocol [MeSH Supplementary Concept]
- LLA-IV-AR protocol [MeSH Supplementary Concept]
- LMB89 protocol [MeSH Supplementary Concept]
- LMF protocol [MeSH Supplementary Concept]
- LMFP protocol [MeSH Supplementary Concept]
- LMV protocol [MeSH Supplementary Concept]
- LNH87-2 protocol [MeSH Supplementary Concept]
- LSA2-L2 protocol [MeSH Supplementary Concept]
- M-BACOD protocol [MeSH Supplementary Concept]
- M-BACOP protocol [MeSH Supplementary Concept]
- M-BACOS protocol [MeSH Supplementary Concept]
- M-BNCOD protocol [MeSH Supplementary Concept]
- M-CAVI protocol [MeSH Supplementary Concept]
- M-DOMP protocol [MeSH Supplementary Concept]
- M-FLP protocol [MeSH Supplementary Concept]
- M-VAC protocol [MeSH Supplementary Concept]
- M-VEC protocol [MeSH Supplementary Concept]
- MAB protocol [MeSH Supplementary Concept]
- MAC III protocol [MeSH Supplementary Concept]
- MAC combination [MeSH Supplementary Concept]
- MACC combination [MeSH Supplementary Concept]
- MACHO protocol [MeSH Supplementary Concept]
- MACOP-B protocol [MeSH Supplementary Concept]
- MACOP-B regimen [MeSH Supplementary Concept]
- MAE protocol [MeSH Supplementary Concept]
- MAPECO protocol [MeSH Supplementary Concept]
- MAPO protocol [MeSH Supplementary Concept]
- MATCOP regimen [MeSH Supplementary Concept]
- MATILDE regimen [MeSH Supplementary Concept]
- MBD protocol [MeSH Supplementary Concept]
- MBVP protocol [MeSH Supplementary Concept]
- MCC protocol [MeSH Supplementary Concept]
- MCHC protocol [MeSH Supplementary Concept]
- MCHOD protocol [MeSH Supplementary Concept]
- MCM protocol [MeSH Supplementary Concept]
- MCNO regimen [MeSH Supplementary Concept]
- MCP 842 regimen [MeSH Supplementary Concept]
- MDACC protocol [MeSH Supplementary Concept]
- MDC protocol [MeSH Supplementary Concept]
- MEA regimen [MeSH Supplementary Concept]
- MEC protocol 1 [MeSH Supplementary Concept]
- MEC protocol 2 [MeSH Supplementary Concept]
- MECHOP-BM protocol [MeSH Supplementary Concept]
- MECY protocol [MeSH Supplementary Concept]
- MEV protocol [MeSH Supplementary Concept]
- MEV-AD protocol [MeSH Supplementary Concept]
- MEVAP protocol [MeSH Supplementary Concept]
- MFAV protocol [MeSH Supplementary Concept]
- MFL protocol [MeSH Supplementary Concept]
- MIME protocol [MeSH Supplementary Concept]
- MIMO protocol [MeSH Supplementary Concept]
- MIMOC protocol [MeSH Supplementary Concept]
- ML-Y1 protocol [MeSH Supplementary Concept]
- MLL-93 protocol [MeSH Supplementary Concept]
- MME protocol [MeSH Supplementary Concept]
- MMIP protocol [MeSH Supplementary Concept]
- MMM protocol 1 [MeSH Supplementary Concept]
- MMM protocol 2 [MeSH Supplementary Concept]
- MNCOP-B protocol [MeSH Supplementary Concept]
- MOMK protocol [MeSH Supplementary Concept]
- MOPLACE protocol [MeSH Supplementary Concept]
- MOPLEC protocol [MeSH Supplementary Concept]
- MP regimen [MeSH Supplementary Concept]
- MPEMi protocol [MeSH Supplementary Concept]
- MPEpiE protocol [MeSH Supplementary Concept]
- MPEpiV protocol [MeSH Supplementary Concept]
- MSK-NY-II protocol, modified [MeSH Supplementary Concept]
- MTX-CF protocol [MeSH Supplementary Concept]
- MTX-CHOP protocol [MeSH Supplementary Concept]
- MV26PD protocol [MeSH Supplementary Concept]
- MVMF protocol [MeSH Supplementary Concept]
- MVMJ protocol [MeSH Supplementary Concept]
- MVP-CAB protocol [MeSH Supplementary Concept]
- Murphy-Bowmann protocol [MeSH Supplementary Concept]
- N(10)-methylfolate [MeSH Supplementary Concept]
- N(alpha)-(4-amino-4-deoxy-10-methylpteroyl)-N(epsilon)-(4-azido-5-iodosalicylyl)lysine [MeSH Supplementary Concept]
- N(alpha)-(4-amino-4-deoxy-N(10)-methylpteroyl)-N-(epsilon)-(5-(N,N-dimethylamino)-1-naphthalenesulfonyl)lysine [MeSH Supplementary Concept]
- N,N,O,O-tetrakis(tert-butyldimethylsilyl)methotrexate [MeSH Supplementary Concept]
- N-(1-((2,4-diamino-6-pteridinyl)methyl)-3,4-dihydro -2H-1,4-benzothiazine-7-carbonyl)-L-2-aminoadipic acid [MeSH Supplementary Concept]
- N-(5-(beta-(2,4-diamino-6-pteridinyl)ethyl)-2-thenoyl)glutamic acid [MeSH Supplementary Concept]
- N-alpha-(4-amino-4-deoxy-N(10)-methylpteroyl)-N(delta)-(5-(N,N-dimethylamino)-1-naphthalenesulfonyl)ornithine [MeSH Supplementary Concept]
- NCI PB 93-C-207 protocol [MeSH Supplementary Concept]
- NEO-MACOP-B protocol [MeSH Supplementary Concept]
- NMF protocol [MeSH Supplementary Concept]
- NSC-98579 [MeSH Supplementary Concept]
- OOS-A regimen [MeSH Supplementary Concept]
- OS 87 protocol [MeSH Supplementary Concept]
- P-COMM-B protocol [MeSH Supplementary Concept]
- PACE-BOM protocol [MeSH Supplementary Concept]
- PBMF protocol [MeSH Supplementary Concept]
- PBML protocol [MeSH Supplementary Concept]
- PCMF protocol [MeSH Supplementary Concept]
- PEA-M regimen [MeSH Supplementary Concept]
- PEEC-M protocol [MeSH Supplementary Concept]
- PETHEMA ALL-3-97 protocol [MeSH Supplementary Concept]
- PFL-MP protocol [MeSH Supplementary Concept]
- PHEA-MTX conjugate [MeSH Supplementary Concept]
- PM-FAC protocol [MeSH Supplementary Concept]
- PMF protocol [MeSH Supplementary Concept]
- PNMF protocol [MeSH Supplementary Concept]
- POG 8493 protocol [MeSH Supplementary Concept]
- POG 8602 protocol [MeSH Supplementary Concept]
- POG-8498 protocol [MeSH Supplementary Concept]
- POMACE protocol [MeSH Supplementary Concept]
- POMB-ACE protocol [MeSH Supplementary Concept]
- POMB-ACE regimen [MeSH Supplementary Concept]
- POMB-ACE-PAV regimen [MeSH Supplementary Concept]
- POMP protocol [MeSH Supplementary Concept]
- PRIME protocol [MeSH Supplementary Concept]
- PROMACE protocol [MeSH Supplementary Concept]
- PROMACE-CytaBOM protocol [MeSH Supplementary Concept]
- Price-Hill protocol [MeSH Supplementary Concept]
- Pro-MACE-C-MOPP protocol [MeSH Supplementary Concept]
- ProMACE-MOPP protocol [MeSH Supplementary Concept]
- ProMECE-CytaBOM protocol [MeSH Supplementary Concept]
- R-14 regimen [MeSH Supplementary Concept]
- SIOP-II protocol [MeSH Supplementary Concept]
- T-6 protocol [MeSH Supplementary Concept]
- T-8801 protocol [MeSH Supplementary Concept]
- T7 protocol [MeSH Supplementary Concept]
- TCCSG B-8801 protocol [MeSH Supplementary Concept]
- TMF protocol [MeSH Supplementary Concept]
- TMM protocol [MeSH Supplementary Concept]
- TNP 351 [MeSH Supplementary Concept]
- TOTAL-XII protocol [MeSH Supplementary Concept]
- TRAMPCO protocol [MeSH Supplementary Concept]
- TRAMPCOL protocol [MeSH Supplementary Concept]
- UCH II protocol [MeSH Supplementary Concept]
- UKALL X protocol [MeSH Supplementary Concept]
- V-CAM protocol [MeSH Supplementary Concept]
- VAAP regimen [MeSH Supplementary Concept]
- VAC-M protocol [MeSH Supplementary Concept]
- VAMA protocol [MeSH Supplementary Concept]
- VAMP combination [MeSH Supplementary Concept]
- VAMP protocol [MeSH Supplementary Concept]
- VAMP-EEE protocol [MeSH Supplementary Concept]
- VBCMF protocol [MeSH Supplementary Concept]
- VBM protocol [MeSH Supplementary Concept]
- VBM protocol 2 [MeSH Supplementary Concept]
- VBMF protocol [MeSH Supplementary Concept]
- VCMA protocol [MeSH Supplementary Concept]
- VEMFAH protocol [MeSH Supplementary Concept]
- VEMP protocol 3 [MeSH Supplementary Concept]
- VEPA-L protocol [MeSH Supplementary Concept]
- VEPA-M protocol [MeSH Supplementary Concept]
- VIM-Bleo protocol [MeSH Supplementary Concept]
- VIM3 protocol [MeSH Supplementary Concept]
- VIM3-ARA C regimen [MeSH Supplementary Concept]
- VIPP-BM protocol [MeSH Supplementary Concept]
- VMBP protocol [MeSH Supplementary Concept]
- VMF protocol [MeSH Supplementary Concept]
- VMF regimen [MeSH Supplementary Concept]
- VMM protocol [MeSH Supplementary Concept]
- VMP protocol [MeSH Supplementary Concept]
- VMP-CIsCF protocol [MeSH Supplementary Concept]
- VMV protocol [MeSH Supplementary Concept]
- VP-BBML protocol [MeSH Supplementary Concept]
- VPC regimen [MeSH Supplementary Concept]
- VTMF protocol [MeSH Supplementary Concept]
- VTMFAP protocol [MeSH Supplementary Concept]
- VTMFP protocol [MeSH Supplementary Concept]
- VbCFM protocol [MeSH Supplementary Concept]
- beta,beta-difluoromethotrexate [MeSH Supplementary Concept]
- biotin-SS-methotrexate [MeSH Supplementary Concept]
- chloromethylketone methotrexate [MeSH Supplementary Concept]
- deoxyaminopteroic acid [MeSH Supplementary Concept]
- dextran T70-methotrexate conjugate [MeSH Supplementary Concept]
- diazoketone methotrexate [MeSH Supplementary Concept]
- dihydromethotrexate [MeSH Supplementary Concept]
- fibrinogen-methotrexate conjugate [MeSH Supplementary Concept]
- fluorescein-methotrexate [MeSH Supplementary Concept]
- fluoresceinated methotrexate [MeSH Supplementary Concept]
- gamma,gamma-difluoromethotrexate [MeSH Supplementary Concept]
- gamma-tert-butyl methotrexate [MeSH Supplementary Concept]
- gamma-tetrazole-methotrexate [MeSH Supplementary Concept]
- hexa CAF protocol [MeSH Supplementary Concept]
- lysine-iodoacetylmethotrexate [MeSH Supplementary Concept]
- lysine-methotrexate [MeSH Supplementary Concept]
- m-ACOD protocol [MeSH Supplementary Concept]
- m-BECOD protocol [MeSH Supplementary Concept]
- m-BOP protocol [MeSH Supplementary Concept]
- m-M-BACOD protocol [MeSH Supplementary Concept]
- mallinson protocol [MeSH Supplementary Concept]
- methotrexate 5-aminoallyl-2'-deoxyuridine 5'-monophosphate [MeSH Supplementary Concept]
- methotrexate N-hydroxysuccinimide ester [MeSH Supplementary Concept]
- methotrexate alpha-aspartate [MeSH Supplementary Concept]
- methotrexate bisphosphonate [MeSH Supplementary Concept]
- methotrexate di-n-butyl ester [MeSH Supplementary Concept]
- methotrexate polyglutamate [MeSH Supplementary Concept]
- methotrexate-3-(aminoethyldithio)propionic acid-poly(lysine) [MeSH Supplementary Concept]
- methotrexate-GIVGPL-dextran [MeSH Supplementary Concept]
- methotrexate-N,N'-bis(decylamide) [MeSH Supplementary Concept]
- methotrexate-N,N'-bis(dodecylamide) [MeSH Supplementary Concept]
- methotrexate-PVGLIG-dextran [MeSH Supplementary Concept]
- methotrexate-alpha glutamate [MeSH Supplementary Concept]
- methotrexate-alpha-alanine [MeSH Supplementary Concept]
- methotrexate-alpha-arginine [MeSH Supplementary Concept]
- methotrexate-alpha-benzyl-gamma-hexadecyl ester [MeSH Supplementary Concept]
- methotrexate-alpha-monoamide [MeSH Supplementary Concept]
- methotrexate-alpha-phenylalanine [MeSH Supplementary Concept]
- methotrexate-gamma-1,2-dimyristoylphosphatidylethanolamine [MeSH Supplementary Concept]
- methotrexate-gamma-aspartate [MeSH Supplementary Concept]
- methotrexate-gamma-dimethylamide [MeSH Supplementary Concept]
- methotrexate-gamma-glycerophosphatidylethanolamine [MeSH Supplementary Concept]
- methotrexate-gamma-hexadecyl ester [MeSH Supplementary Concept]
- methotrexate-gamma-methylamide [MeSH Supplementary Concept]
- methotrexate-gamma-monoamide [MeSH Supplementary Concept]
- methotrexate-homocysteic acid [MeSH Supplementary Concept]
- methotrexate-polylysine [MeSH Supplementary Concept]
- methotrexate-serum albumin [MeSH Supplementary Concept]
- mito-MBD protocol [MeSH Supplementary Concept]
- modified M-VAC protocol [MeSH Supplementary Concept]
- new york protocol [MeSH Supplementary Concept]
- non-Hodgkin's lymphoma protocol 8503 [MeSH Supplementary Concept]
- ornithine-methotrexate [MeSH Supplementary Concept]
- pea seed lectin-methotrexate conjugate [MeSH Supplementary Concept]
- protocol 8001 [MeSH Supplementary Concept]
- regimen B [MeSH Supplementary Concept]
- rizzoli IOR protocol [MeSH Supplementary Concept]
- rosen's T-10 protocol [MeSH Supplementary Concept]
- st jude's regimen [MeSH Supplementary Concept]
- stanford university protocol [MeSH Supplementary Concept]
- tetrahydro-3',5'-dichloromethotrexate [MeSH Supplementary Concept]
- tetrahydromethotrexate [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Methotrexate [ACR pathology]
- Product containing methotrexate (medicinal product) [SNOMED CT concept]
- d-(-)-n-(2,4-diamino-6-pteridinyl(dimethylamino)benzoyl)glutamic acid [Substance BNPC]
- n-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-dl-glutamic acid [Substance BNPC]
- toxic accident due to methotrexate [Indication]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Methotrexate [LOINC component]
- Methotrexate [ICD-11 Extension code]
- Methotrexate [NCIt concept]
- Methotrexate (substance) [SNOMED CT concept]
- Product containing methotrexate (medicinal product) [SNOMED CT concept]
- methotrexate [ATC Code]
- methotrexate [ATC Code]
- methotrexate [Substance BNPC]
- methotrexate [SNOMED Notion]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients